Coronary Artery DiseaseCORO-CTAIOMICSNCT06029777
Peri-luminal COROnary CTa AI-driven radiOMICS to Identify Vulnerable Patients (CORO-CTAIOMICS)
An observational study of Coronary Artery Disease, run by IRCCS San Raffaele at 1 site in Italy.
Trial summary
CAD is a leading cause of mortality in Europe. cCTA is recommended to rule out obstructive CAD, but, in most patients, it shows non-obstructive CAD. The management of these patients is unclear due to lack of reproducible quantitative measurement, beyond stenosis severity, capable to assess the risk of disease… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease
- How many people
- 2,190 participants
- Where
- 1 siteItaly
- Study dates
- 31 Jul 2023to 24 Sep 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients undergoing clinically indicated cCTA for suspected CAD.
Who may be able to join
- Patients with CT performed for CAD assessment between 2017 and 2019.
- Follow-up duration of at least 4 years.
Who cannot join
- Refusal to participate in the study
- Age <18 years old
- History of previous coronary revascularization
- Presence of other cardiovascular comorbidities (e.g. inflammatory cardiomyopathy, valvular cardiomyopathy, idiopathic dilated cardiomyopathy, infiltrative cardiomyopathy)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Peri-luminal COROnary CTa AI-driven radiOMICS to Identify Vulnerable Patients
CAD is a leading cause of mortality in Europe. cCTA is recommended to rule out obstructive CAD, but, in most patients, it shows non-obstructive CAD. The management of these patients is unclear due to lack of reproducible quantitative measurement, beyond stenosis severity, capable to assess the risk of disease progression towards developing MACEs. To improve identification and phenotypization of patients at high risk of disease progression, the investigators propose the application of artificial intelligence algorithms to cCTA images to automatically extract periluminal radiomics features to characterize the atherosclerotic process. By leveraging machine-learning empowered radiomics the investigators aim to improve patients' risk stratification in a robust, quantitative and reproducible fashion. By developing a novel quantitative AI based cCTA measure, the investigators expect to provide a risk score capable to identify patients who can benefit of a more aggressive medical treatment and management, thus improving outcome
Read the detailed description
Background and rationale
In the last years, cCTA has become a pivotal diagnostic tool in the setting of suspected CAD. The latest ESC guidelines recommend cCTA as the first line diagnostic test for patients with symptoms suspected to originate from CAD, especially in intermediate pre-test probability (15 to 85%). patients. The AHA and Italian guidelines essentially suggest the same approach. The recommendations are based on the extremely high accuracy of cCTA in ruling-out obstructive CAD. As result the investigators assist to a tremendous increase in the number of patients undergoing CCTA in the daily clinical routine. Most of these patients (80%) result to not have obstructive CAD, but this result does not mean that all this patients are at low risk. The prognostic stratification of these patients is still an urgent unmet need. Among patients with absence of obstructive CAD the investigators found patients with different degree of atherosclerotic burden and patients with different kind of plaques (high or low risk plaques) and different degrees of coronary wall and pericoronary inflammation. The prognostic stratification of these patients is still an urgent unmet need. The cCTA images include a lot of information with a great potential informative content about the atherosclerotic burden and the vulnerability of the non-obstructive CAD of each single patients, but all these information are not currently exploited in the clinical routine to change the patients management for a lack of robust and reproducible tools to extract this data in quantitative way and o integrate them in a prognostic risk score.
In the last years, it has been shown that coronary artery plaque characteristics (e.g. lesion length, volume, stenosis, attenuation, remodeling index, etc) (2) and pericoronary adipose tissue (3) attenuation carry a significant prognostic value. However, it is known that many of these biomarkers suffer from low reproducibility, mainly due to technical constrains in automatic or semiautomatic separation of plaques from surrounding adipose tissue. This may cause the incorrect inclusion of plaques into the segmentation of pericoronary adipose tissue and vice-versa, leading to unreliable results in the assessment of plaque burden and plaque attenuation (4). Furthermore, the qualitative or semiquantitative evaluation of the aforementioned plaque characteristics and pericoronary fat density might reflect only part of the information available. In this scenario, radiomics-based assessment may unveil information hidden to the human eye, leading to better risk stratification of cardiovascular risk (5, 6).
This study adds two major improvements in prognostic risk stratification based on cCTA plaque and adipose tissue analysis. First, the investigators propose a method to segment both the plaques and the pericoronary adipose tissue easily and independently by semiautomatic or automatic identification of the edge between plaque and fat (which is critical). In fact, this tool will perform a segmentation of all the tissue included in a circular range outside the coronary lumen with a diameter based on the lumen diameter itself. This technical solution will greatly increase reproducibility of segmentation. Secondly, the investigators propose the use radiomics to analyze this circular pericoronary milieu, potentially individuating novel biomarkers -invisible to human eye- of CAD instability capable of providing important prognostic value.
In detail, the novelty of this research lies in the fact that 1) pericoronary adipose tissue and plaques will be treated as a single milieu, thus significantly reducing the effort for accurate tissue segmentation and reducing reproducibility concerns; 2) radiomics will be applied to extract meaningful information invisible to human eye capable. Furthermore, this radiomics approach will be supported by machine learning (ML) models including regularized regression, genetic algorithms and deep learning, due to the capability of ML to directly manage and assess the huge amount of data extracted from the radiological images. Thus, the final outcome of this research will be an algorithm capable of predicting the risk of MACEs of the single patient by automatically analyzing peri-luminal coronary tissue radiomics data derived from cCTA performed in the routine clinical practice.
- Conditions
- Coronary Artery Disease
- Keywords
- Coronary artery disease, Computed Tomography, Radiomic, Artificial Intelligence, Risk assessment, Major adverse cardiac events
- Medical subject headings
- Coronary Artery Disease, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Retrospective cohort | The retrospective cohort will include 2190 patients who underwent a clinically indicated cCTA between 2017 and 2019 at the Radiology Unit of San Raffaele Hospital. No other interventions will be performed. Patients will be solely contacted via a telephone call to assess their clinical status. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite outcome
All-cause mortality, myocardial infarction, due to unstable angina or heart hospitalization failure, late coronary revascularization
Measured: 48 months from CCTA
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2023
- Study start31 Jul 2023
- Primary completion24 Sep 2024
- Study completion24 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- More trials run by IRCCS San RaffaeleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 2,190 participants (actual)
Sponsor and investigators
- Lead sponsor
- IRCCS San Raffaele
- Sponsor type
- University, hospital or other
- Collaborators
- Ministry of Health, Italy
- Responsible party
- Principal investigator, Antonio Esposito, IRCCS San Raffaele
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06029777
- Sponsor's protocol ID
- PNRR-MAD-2022-12376633
- Acronym
- CORO-CTAIOMICS
- Status last verified
- Jan 2026
- First submitted
- 1 Sep 2023
- Last updated
- 15 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE Jr, Moons KG, Collins GS. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2019 Mar 30;38(7):1276-1296. doi: 10.1002/sim.7992. Epub 2018 Oct 24.
PubMed 30357870Nerlekar N, Ha FJ, Cheshire C, Rashid H, Cameron JD, Wong DT, Seneviratne S, Brown AJ. Computed Tomographic Coronary Angiography-Derived Plaque Characteristics Predict Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Circ Cardiovasc Imaging. 2018 Jan;11(1):e006973. doi: 10.1161/CIRCIMAGING.117.006973.
PubMed 29305348Goeller M, Achenbach S, Herrmann N, Bittner DO, Kilian T, Dey D, Raaz-Schrauder D, Marwan M. Pericoronary adipose tissue CT attenuation and its association with serum levels of atherosclerosis-relevant inflammatory mediators, coronary calcification and major adverse cardiac events. J Cardiovasc Comput Tomogr. 2021 Sep-Oct;15(5):449-454. doi: 10.1016/j.jcct.2021.03.005. Epub 2021 Apr 3.
PubMed 33867303Tzolos E, McElhinney P, Williams MC, Cadet S, Dweck MR, Berman DS, Slomka PJ, Newby DE, Dey D. Repeatability of quantitative pericoronary adipose tissue attenuation and coronary plaque burden from coronary CT angiography. J Cardiovasc Comput Tomogr. 2021 Jan-Feb;15(1):81-84. doi: 10.1016/j.jcct.2020.03.007. Epub 2020 Apr 14.
PubMed 32312662Kolossvary M, Karady J, Szilveszter B, Kitslaar P, Hoffmann U, Merkely B, Maurovich-Horvat P. Radiomic Features Are Superior to Conventional Quantitative Computed Tomographic Metrics to Identify Coronary Plaques With Napkin-Ring Sign. Circ Cardiovasc Imaging. 2017 Dec;10(12):e006843. doi: 10.1161/CIRCIMAGING.117.006843.
PubMed 29233836Lin A, Kolossvary M, Yuvaraj J, Cadet S, McElhinney PA, Jiang C, Nerlekar N, Nicholls SJ, Slomka PJ, Maurovich-Horvat P, Wong DTL, Dey D. Myocardial Infarction Associates With a Distinct Pericoronary Adipose Tissue Radiomic Phenotype: A Prospective Case-Control Study. JACC Cardiovasc Imaging. 2020 Nov;13(11):2371-2383. doi: 10.1016/j.jcmg.2020.06.033. Epub 2020 Aug 26.
PubMed 32861654Varma S, Simon R. Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics. 2006 Feb 23;7:91. doi: 10.1186/1471-2105-7-91.
PubMed 16504092Emerson RW, Adams C, Nishino T, Hazlett HC, Wolff JJ, Zwaigenbaum L, Constantino JN, Shen MD, Swanson MR, Elison JT, Kandala S, Estes AM, Botteron KN, Collins L, Dager SR, Evans AC, Gerig G, Gu H, McKinstry RC, Paterson S, Schultz RT, Styner M; IBIS Network; Schlaggar BL, Pruett JR Jr, Piven J. Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age. Sci Transl Med. 2017 Jun 7;9(393):eaag2882. doi: 10.1126/scitranslmed.aag2882.
PubMed 28592562Brown PJ, Zhong J, Frood R, Currie S, Gilbert A, Appelt AL, Sebag-Montefiore D, Scarsbrook A. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT. Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2790-2799. doi: 10.1007/s00259-019-04495-1. Epub 2019 Sep 4.
PubMed 31482428Bardosi ZR, Dejaco D, Santer M, Kloppenburg M, Mangesius S, Widmann G, Ganswindt U, Rumpold G, Riechelmann H, Freysinger W. Benchmarking Eliminative Radiomic Feature Selection for Head and Neck Lymph Node Classification. Cancers (Basel). 2022 Jan 18;14(3):477. doi: 10.3390/cancers14030477.
PubMed 35158745Cho HH, Lee HY, Kim E, Lee G, Kim J, Kwon J, Park H. Radiomics-guided deep neural networks stratify lung adenocarcinoma prognosis from CT scans. Commun Biol. 2021 Nov 12;4(1):1286. doi: 10.1038/s42003-021-02814-7.
PubMed 34773070Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006 Nov-Dec;26(6):565-74. doi: 10.1177/0272989X06295361.
PubMed 17099194Saito T, Rehmsmeier M. The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets. PLoS One. 2015 Mar 4;10(3):e0118432. doi: 10.1371/journal.pone.0118432. eCollection 2015.
PubMed 25738806
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Peri-luminal COROnary CTa AI-driven radiOMICS to Identify Vulnerable Patients
- ClinicalTrials.gov ID
- NCT06029777
- Acronym / sponsor ID
- CORO-CTAIOMICS / PNRR-MAD-2022-12376633
- Conditions
- Coronary Artery Disease
- Keywords
- Coronary artery disease, Computed Tomography, Radiomic, Artificial Intelligence, Risk assessment, Major adverse cardiac events
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,190 participants (actual)
- Lead sponsor
- IRCCS San RaffaeleUniversity, hospital or other
- Collaborators
- Ministry of Health, Italy
- Study start
- 31 Jul 2023 (actual)
- Primary completion
- 24 Sep 2024 (actual)
- Study completion
- 24 Sep 2024 (actual)
- First posted
- 8 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CAD is a leading cause of mortality in Europe. cCTA is recommended to rule out obstructive CAD, but, in most patients, it shows non-obstructive CAD. The management of these patients is unclear due to lack of reproducible quantitative measurement, beyond stenosis severity, capable to assess the risk of disease progression towards developing MACEs. To improve identification and phenotypization of patients at high risk of disease progression, the investigators propose the application of artificial intelligence algorithms to cCTA images to automatically extract periluminal radiomics features to characterize the atherosclerotic process. By leveraging machine-learning empowered radiomics the investigators aim to improve patients' risk stratification in a robust, quantitative and reproducible fashion. By developing a novel quantitative AI based cCTA measure, the investigators expect to provide a risk score capable to identify patients who can benefit of a more aggressive medical treatment and management, thus improving outcome
Detailed description
Background and rationale
In the last years, cCTA has become a pivotal diagnostic tool in the setting of suspected CAD. The latest ESC guidelines recommend cCTA as the first line diagnostic test for patients with symptoms suspected to originate from CAD, especially in intermediate pre-test probability (15 to 85%). patients. The AHA and Italian guidelines essentially suggest the same approach. The recommendations are based on the extremely high accuracy of cCTA in ruling-out obstructive CAD. As result the investigators assist to a tremendous increase in the number of patients undergoing CCTA in the daily clinical routine. Most of these patients (80%) result to not have obstructive CAD, but this result does not mean that all this patients are at low risk. The prognostic stratification of these patients is still an urgent unmet need. Among patients with absence of obstructive CAD the investigators found patients with different degree of atherosclerotic burden and patients with different kind of plaques (high or low risk plaques) and different degrees of coronary wall and pericoronary inflammation. The prognostic stratification of these patients is still an urgent unmet need. The cCTA images include a lot of information with a great potential informative content about the atherosclerotic burden and the vulnerability of the non-obstructive CAD of each single patients, but all these information are not currently exploited in the clinical routine to change the patients management for a lack of robust and reproducible tools to extract this data in quantitative way and o integrate them in a prognostic risk score.
In the last years, it has been shown that coronary artery plaque characteristics (e.g. lesion length, volume, stenosis, attenuation, remodeling index, etc) (2) and pericoronary adipose tissue (3) attenuation carry a significant prognostic value. However, it is known that many of these biomarkers suffer from low reproducibility, mainly due to technical constrains in automatic or semiautomatic separation of plaques from surrounding adipose tissue. This may cause the incorrect inclusion of plaques into the segmentation of pericoronary adipose tissue and vice-versa, leading to unreliable results in the assessment of plaque burden and plaque attenuation (4). Furthermore, the qualitative or semiquantitative evaluation of the aforementioned plaque characteristics and pericoronary fat density might reflect only part of the information available. In this scenario, radiomics-based assessment may unveil information hidden to the human eye, leading to better risk stratification of cardiovascular risk (5, 6).
This study adds two major improvements in prognostic risk stratification based on cCTA plaque and adipose tissue analysis. First, the investigators propose a method to segment both the plaques and the pericoronary adipose tissue easily and independently by semiautomatic or automatic identification of the edge between plaque and fat (which is critical). In fact, this tool will perform a segmentation of all the tissue included in a circular range outside the coronary lumen with a diameter based on the lumen diameter itself. This technical solution will greatly increase reproducibility of segmentation. Secondly, the investigators propose the use radiomics to analyze this circular pericoronary milieu, potentially individuating novel biomarkers -invisible to human eye- of CAD instability capable of providing important prognostic value.
In detail, the novelty of this research lies in the fact that 1) pericoronary adipose tissue and plaques will be treated as a single milieu, thus significantly reducing the effort for accurate tissue segmentation and reducing reproducibility concerns; 2) radiomics will be applied to extract meaningful information invisible to human eye capable. Furthermore, this radiomics approach will be supported by machine learning (ML) models including regularized regression, genetic algorithms and deep learning, due to the capability of ML to directly manage and assess the huge amount of data extracted from the radiological images. Thus, the final outcome of this research will be an algorithm capable of predicting the risk of MACEs of the single patient by automatically analyzing peri-luminal coronary tissue radiomics data derived from cCTA performed in the routine clinical practice.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Retrospective cohort | – | –The retrospective cohort will include 2190 patients who underwent a clinically indicated cCTA between 2017 and 2019 at the Radiology Unit of San Raffaele Hospital. No other interventions will be performed. Patients will be solely contacted via a telephone call to assess their clinical status. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients undergoing clinically indicated cCTA for suspected CAD.
Key inclusion criteria (2 listed)
- Patients with CT performed for CAD assessment between 2017 and 2019.
- Follow-up duration of at least 4 years.
Key exclusion criteria (4 listed)
- Refusal to participate in the study
- Age <18 years old
- History of previous coronary revascularization
- Presence of other cardiovascular comorbidities (e.g. inflammatory cardiomyopathy, valvular cardiomyopathy, idiopathic dilated cardiomyopathy, infiltrative cardiomyopathy)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Composite outcome
Time frame: 48 months from CCTA
All-cause mortality, myocardial infarction, due to unstable angina or heart hospitalization failure, late coronary revascularization
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2026.
- Background: PubMed 30357870Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE Jr, Moons KG, Collins GS. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2019 Mar 30;38(7):1276-1296. doi: 10.1002/sim.7992. Epub 2018 Oct 24.
- Background: PubMed 29305348Nerlekar N, Ha FJ, Cheshire C, Rashid H, Cameron JD, Wong DT, Seneviratne S, Brown AJ. Computed Tomographic Coronary Angiography-Derived Plaque Characteristics Predict Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Circ Cardiovasc Imaging. 2018 Jan;11(1):e006973. doi: 10.1161/CIRCIMAGING.117.006973.
- Background: PubMed 33867303Goeller M, Achenbach S, Herrmann N, Bittner DO, Kilian T, Dey D, Raaz-Schrauder D, Marwan M. Pericoronary adipose tissue CT attenuation and its association with serum levels of atherosclerosis-relevant inflammatory mediators, coronary calcification and major adverse cardiac events. J Cardiovasc Comput Tomogr. 2021 Sep-Oct;15(5):449-454. doi: 10.1016/j.jcct.2021.03.005. Epub 2021 Apr 3.
- Background: PubMed 32312662Tzolos E, McElhinney P, Williams MC, Cadet S, Dweck MR, Berman DS, Slomka PJ, Newby DE, Dey D. Repeatability of quantitative pericoronary adipose tissue attenuation and coronary plaque burden from coronary CT angiography. J Cardiovasc Comput Tomogr. 2021 Jan-Feb;15(1):81-84. doi: 10.1016/j.jcct.2020.03.007. Epub 2020 Apr 14.
- Background: PubMed 29233836Kolossvary M, Karady J, Szilveszter B, Kitslaar P, Hoffmann U, Merkely B, Maurovich-Horvat P. Radiomic Features Are Superior to Conventional Quantitative Computed Tomographic Metrics to Identify Coronary Plaques With Napkin-Ring Sign. Circ Cardiovasc Imaging. 2017 Dec;10(12):e006843. doi: 10.1161/CIRCIMAGING.117.006843.
- Background: PubMed 32861654Lin A, Kolossvary M, Yuvaraj J, Cadet S, McElhinney PA, Jiang C, Nerlekar N, Nicholls SJ, Slomka PJ, Maurovich-Horvat P, Wong DTL, Dey D. Myocardial Infarction Associates With a Distinct Pericoronary Adipose Tissue Radiomic Phenotype: A Prospective Case-Control Study. JACC Cardiovasc Imaging. 2020 Nov;13(11):2371-2383. doi: 10.1016/j.jcmg.2020.06.033. Epub 2020 Aug 26.
- Background: PubMed 16504092Varma S, Simon R. Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics. 2006 Feb 23;7:91. doi: 10.1186/1471-2105-7-91.
- Background: PubMed 28592562Emerson RW, Adams C, Nishino T, Hazlett HC, Wolff JJ, Zwaigenbaum L, Constantino JN, Shen MD, Swanson MR, Elison JT, Kandala S, Estes AM, Botteron KN, Collins L, Dager SR, Evans AC, Gerig G, Gu H, McKinstry RC, Paterson S, Schultz RT, Styner M; IBIS Network; Schlaggar BL, Pruett JR Jr, Piven J. Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age. Sci Transl Med. 2017 Jun 7;9(393):eaag2882. doi: 10.1126/scitranslmed.aag2882.
- Background: PubMed 31482428Brown PJ, Zhong J, Frood R, Currie S, Gilbert A, Appelt AL, Sebag-Montefiore D, Scarsbrook A. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT. Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2790-2799. doi: 10.1007/s00259-019-04495-1. Epub 2019 Sep 4.
- Background: PubMed 35158745Bardosi ZR, Dejaco D, Santer M, Kloppenburg M, Mangesius S, Widmann G, Ganswindt U, Rumpold G, Riechelmann H, Freysinger W. Benchmarking Eliminative Radiomic Feature Selection for Head and Neck Lymph Node Classification. Cancers (Basel). 2022 Jan 18;14(3):477. doi: 10.3390/cancers14030477.
- Background: PubMed 34773070Cho HH, Lee HY, Kim E, Lee G, Kim J, Kwon J, Park H. Radiomics-guided deep neural networks stratify lung adenocarcinoma prognosis from CT scans. Commun Biol. 2021 Nov 12;4(1):1286. doi: 10.1038/s42003-021-02814-7.
- Background: PubMed 17099194Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006 Nov-Dec;26(6):565-74. doi: 10.1177/0272989X06295361.
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease, run by IRCCS San Raffaele at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite outcome (time frame: 48 months from CCTA). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06029777, which also lists 13 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2026.